PE20210045A1 - Anticuerpos agonistas contra pd-1 y usos de estos - Google Patents
Anticuerpos agonistas contra pd-1 y usos de estosInfo
- Publication number
- PE20210045A1 PE20210045A1 PE2020001188A PE2020001188A PE20210045A1 PE 20210045 A1 PE20210045 A1 PE 20210045A1 PE 2020001188 A PE2020001188 A PE 2020001188A PE 2020001188 A PE2020001188 A PE 2020001188A PE 20210045 A1 PE20210045 A1 PE 20210045A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- whose amino
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 102000048362 human PDCD1 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se refiere a un anticuerpo que se fija a la PD-1 humana, que comprende: 1) una region variable de la cadena pesada (HCVR) cuya secuencia de aminoacidos es la SEQ ID NO:3; y 2) una region variable de la cadena liviana (LCVR) cuya secuencia de aminoacidos es la SEQ ID NO:4 , en donde la HCVR comprende una HCDR1, HCDR2 y HCDR3, y la LCVR comprende una LCDR1, LCDR2, y LCDR3, en donde la secuencia de aminoacidos de la HCDR1 es la SEQ ID NO: 5, HCDR2 es la SEQ ID NO: 6 y HCDR3 es la SEQ ID NO: 7, la secuencia de aminoacidos de la LCDR1 es la SEQ ID NO: 8, LCDR2 es la SEQ ID NO: 9 y LCDR3 es la SEQ ID NO: 10, y en donde el anticuerpo es una IgG1. Comprende ademas una HC cuya secuencia de aminoacidos es la SEQ ID NO:1 y una LC cuya secuencia de aminoacidos es la SEQ ID NO:2. Tambien se refiere a una composicion farmaceutica que comprende dicho anticuerpo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637643P | 2018-03-02 | 2018-03-02 | |
| PCT/US2019/019076 WO2019168745A1 (en) | 2018-03-02 | 2019-02-22 | Pd-1 agonist antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210045A1 true PE20210045A1 (es) | 2021-01-08 |
Family
ID=65686121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001188A PE20210045A1 (es) | 2018-03-02 | 2019-02-22 | Anticuerpos agonistas contra pd-1 y usos de estos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10493148B2 (es) |
| EP (1) | EP3759139A1 (es) |
| JP (3) | JP7071521B2 (es) |
| KR (2) | KR102536014B1 (es) |
| CN (1) | CN111886253A (es) |
| AR (1) | AR114127A1 (es) |
| AU (2) | AU2019228474B2 (es) |
| BR (1) | BR112020015983A2 (es) |
| CA (1) | CA3092064C (es) |
| CL (1) | CL2020002180A1 (es) |
| CO (1) | CO2020010188A2 (es) |
| CR (1) | CR20200375A (es) |
| DO (1) | DOP2020000153A (es) |
| EA (1) | EA202091809A1 (es) |
| EC (1) | ECSP20053544A (es) |
| IL (1) | IL276340A (es) |
| JO (1) | JOP20200210A1 (es) |
| MA (1) | MA52414A (es) |
| MX (1) | MX2020009124A (es) |
| PE (1) | PE20210045A1 (es) |
| PH (1) | PH12020551463A1 (es) |
| SA (1) | SA520420082B1 (es) |
| SG (1) | SG11202008437WA (es) |
| TW (1) | TWI708787B (es) |
| WO (1) | WO2019168745A1 (es) |
| ZA (1) | ZA202004601B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3362074B1 (en) * | 2015-10-16 | 2023-08-09 | President and Fellows of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| US10961310B2 (en) | 2017-03-15 | 2021-03-30 | Pandion Operations, Inc. | Targeted immunotolerance |
| BR112019024127A2 (pt) | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
| CA3065516A1 (en) | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that specifically bind pd-1 and methods of use |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US20210061912A1 (en) * | 2018-03-20 | 2021-03-04 | WuXi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| CN114679909A (zh) | 2019-05-20 | 2022-06-28 | 潘迪恩运营公司 | MAdCAM靶向的免疫耐受 |
| MX2022013334A (es) * | 2020-04-22 | 2022-12-06 | Igm Biosciences Inc | Moleculas de union multimerica de agonistas de pd-1. |
| WO2021241523A1 (ja) * | 2020-05-25 | 2021-12-02 | 公益財団法人神戸医療産業都市推進機構 | Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物 |
| AU2021280232A1 (en) | 2020-05-26 | 2022-12-15 | Boehringer Ingelheim International Gmbh | Anti-PD-1 antibodies |
| IL307887A (en) | 2021-05-13 | 2023-12-01 | Foundation For Biomedical Res And Innovation At Kobe | An anti-human PD-1 agonist antibody and a pharmaceutical preparation comprising the antibody for the treatment or prevention of inflammatory diseases |
| TW202323301A (zh) | 2021-11-19 | 2023-06-16 | 英商米羅比奧有限公司 | 經工程改造之ｐｄ－１抗體及其用途 |
| WO2023200796A1 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Immune cell inhibition by immune checkpoint engagers |
| WO2024010861A2 (en) * | 2022-07-06 | 2024-01-11 | Santa Ana Bio, Inc. | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |
| WO2024040206A2 (en) * | 2022-08-19 | 2024-02-22 | Eli Lilly And Company | Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody |
| WO2024050421A2 (en) * | 2022-08-30 | 2024-03-07 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting programmed cell death protein 1 (pd-1) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2009026472A1 (en) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Methods for inducing tolerance |
| CA2736816C (en) * | 2008-09-12 | 2018-05-22 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Ｐｄ−１特異抗体およびその使用 |
| EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| EP2742953B1 (en) * | 2011-08-11 | 2021-09-22 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| CN105431449B (zh) | 2013-04-05 | 2021-08-24 | 港大科桥有限公司 | 新的pd1同种型及其用于加强免疫应答的用途 |
| US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| AU2015298356B2 (en) | 2014-08-05 | 2020-11-19 | MabQuest SA | Immunological reagents binding to pd-1 |
| WO2016210129A1 (en) | 2015-06-23 | 2016-12-29 | Memorial Sloan-Kettering Cancer Center | Novel pd-1 immune modulating agents |
| KR20180054824A (ko) | 2015-09-29 | 2018-05-24 | 셀진 코포레이션 | Pd-1 결합 단백질 및 이의 사용 방법 |
| JP6654694B2 (ja) | 2015-10-02 | 2020-02-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ１抗体と使用方法 |
| RU2750675C1 (ru) | 2015-10-02 | 2021-07-01 | Симфоген А/С | Антитела против pd-1 и композиции |
| CN109152798B (zh) | 2015-12-02 | 2022-10-21 | 斯特库比股份有限公司 | 特异于糖基化的pd-1的抗体及其使用方法 |
| CA3065516A1 (en) | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that specifically bind pd-1 and methods of use |
-
2019
- 2019-02-18 TW TW108105310A patent/TWI708787B/zh active
- 2019-02-18 AR ARP190100406A patent/AR114127A1/es unknown
- 2019-02-22 MA MA052414A patent/MA52414A/fr unknown
- 2019-02-22 KR KR1020207024945A patent/KR102536014B1/ko active IP Right Grant
- 2019-02-22 CR CR20200375A patent/CR20200375A/es unknown
- 2019-02-22 US US16/282,609 patent/US10493148B2/en active Active
- 2019-02-22 EP EP19709336.2A patent/EP3759139A1/en active Pending
- 2019-02-22 CN CN201980016779.7A patent/CN111886253A/zh active Pending
- 2019-02-22 JP JP2020545727A patent/JP7071521B2/ja active Active
- 2019-02-22 CA CA3092064A patent/CA3092064C/en active Active
- 2019-02-22 JO JOP/2020/0210A patent/JOP20200210A1/ar unknown
- 2019-02-22 PE PE2020001188A patent/PE20210045A1/es unknown
- 2019-02-22 KR KR1020237017035A patent/KR20230079458A/ko active Application Filing
- 2019-02-22 AU AU2019228474A patent/AU2019228474B2/en active Active
- 2019-02-22 BR BR112020015983-2A patent/BR112020015983A2/pt unknown
- 2019-02-22 MX MX2020009124A patent/MX2020009124A/es unknown
- 2019-02-22 SG SG11202008437WA patent/SG11202008437WA/en unknown
- 2019-02-22 WO PCT/US2019/019076 patent/WO2019168745A1/en active Application Filing
- 2019-02-22 EA EA202091809A patent/EA202091809A1/ru unknown
-
2020
- 2020-07-24 ZA ZA2020/04601A patent/ZA202004601B/en unknown
- 2020-07-28 IL IL276340A patent/IL276340A/en unknown
- 2020-08-05 DO DO2020000153A patent/DOP2020000153A/es unknown
- 2020-08-19 CO CONC2020/0010188A patent/CO2020010188A2/es unknown
- 2020-08-24 CL CL2020002180A patent/CL2020002180A1/es unknown
- 2020-09-01 EC ECSENADI202053544A patent/ECSP20053544A/es unknown
- 2020-09-01 PH PH12020551463A patent/PH12020551463A1/en unknown
- 2020-09-02 SA SA520420082A patent/SA520420082B1/ar unknown
-
2022
- 2022-03-07 JP JP2022034413A patent/JP7259107B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061724A patent/JP2023093549A/ja active Pending
- 2023-07-10 AU AU2023204569A patent/AU2023204569A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| CU24636B1 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| NZ603607A (en) | Cgrp antibodies | |
| NZ583605A (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| RS53661B1 (en) | HIGH AFINITY ANTIBODY ANTIBODIES TO THE HUMAN NERVOUS FACTOR OF GROWTH | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins |